These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 25661587)
1. Correlation between microstructure and bioequivalence in anti-HIV drug efavirenz. Fandaruff C; Segatto Silva MA; Galindo Bedor DC; de Santana DP; Rocha HV; Rebuffi L; Azanza Ricardo CL; Scardi P; Cuffini SL Eur J Pharm Biopharm; 2015 Apr; 91():52-8. PubMed ID: 25661587 [TBL] [Abstract][Full Text] [Related]
2. Nanosuspension of efavirenz for improved oral bioavailability: formulation optimization, in vitro, in situ and in vivo evaluation. Patel GV; Patel VB; Pathak A; Rajput SJ Drug Dev Ind Pharm; 2014 Jan; 40(1):80-91. PubMed ID: 23323843 [TBL] [Abstract][Full Text] [Related]
3. Enhanced oral bioavailability of the antiretroviral efavirenz encapsulated in poly(epsilon-caprolactone) nanoparticles by a spray-drying method. Tshweu L; Katata L; Kalombo L; Chiappetta DA; Hocht C; Sosnik A; Swai H Nanomedicine (Lond); 2014; 9(12):1821-33. PubMed ID: 24364871 [TBL] [Abstract][Full Text] [Related]
4. Sex-by-formulation interaction assessed through a bioequivalence study of efavirenz tablets. Ibarra M; Magallanes L; Lorier M; Vázquez M; Fagiolino P Eur J Pharm Sci; 2016 Mar; 85():106-11. PubMed ID: 26850681 [TBL] [Abstract][Full Text] [Related]
5. Mechanical activation of Efavirenz: the effects on the dissolution and inhibitory behavior. Cappelletto E; Firrito C; Pizzato M; Rebuffi L; Scardi P Pharm Dev Technol; 2018 Dec; 23(10):1128-1135. PubMed ID: 29688125 [TBL] [Abstract][Full Text] [Related]
6. Plasma efavirenz in HIV infected children treated with generic antiretroviral drugs in India. Ramachandran G; Kumar AK; Vasantha M; Shah I; Swaminathan S Indian Pediatr; 2010 Oct; 47(10):890-1. PubMed ID: 21048244 [TBL] [Abstract][Full Text] [Related]
7. Solubility and dissolution enhancement of efavirenz hot melt extruded amorphous solid dispersions using combination of polymeric blends: A QbD approach. Pawar J; Tayade A; Gangurde A; Moravkar K; Amin P Eur J Pharm Sci; 2016 Jun; 88():37-49. PubMed ID: 27049050 [TBL] [Abstract][Full Text] [Related]
9. Efavirenz Dissolution Enhancement IV-Antisolvent Nanocrystallization by Sonication, Physical Stability, and Dissolution. Sartori GJ; Prado LD; Rocha HVA AAPS PharmSciTech; 2017 Nov; 18(8):3011-3020. PubMed ID: 28493004 [TBL] [Abstract][Full Text] [Related]
10. [Data on rilpivirine in treatment-naïve patients. Lessons from ECHO, THRIVE and STaR]. Domingo P; Ribera E Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():20-9. PubMed ID: 24252530 [TBL] [Abstract][Full Text] [Related]
11. In vitro-in vivo correlation of efavirenz tablets using GastroPlus®. Honório Tda S; Pinto EC; Rocha HV; Esteves VS; dos Santos TC; Castro HC; Rodrigues CR; de Sousa VP; Cabral LM AAPS PharmSciTech; 2013 Sep; 14(3):1244-54. PubMed ID: 23943401 [TBL] [Abstract][Full Text] [Related]
12. Efavirenz-loaded polymeric micelles for pediatric anti-HIV pharmacotherapy with significantly higher oral bioavailability [corrected]. Chiappetta DA; Hocht C; Taira C; Sosnik A Nanomedicine (Lond); 2010 Jan; 5(1):11-23. PubMed ID: 20025460 [TBL] [Abstract][Full Text] [Related]
13. Targeting of AIDS related encephalopathy using phenylalanine anchored lipidic nanocarrier. Vyas A; Jain A; Hurkat P; Jain A; Jain SK Colloids Surf B Biointerfaces; 2015 Jul; 131():155-61. PubMed ID: 25988279 [TBL] [Abstract][Full Text] [Related]
14. Does tenofovir influence efavirenz pharmacokinetics? Rotger M; Colombo S; Furrer H; Décosterd L; Buclin T; Telenti A Antivir Ther; 2007; 12(1):115-8. PubMed ID: 17503755 [TBL] [Abstract][Full Text] [Related]
15. Powder for reconstitution of the anti-HIV-1 drug TMC278 - Formulation development, stability and animal studies. Van Gyseghem E; Pendela M; Baert L; Rosier J; Van 't Klooster G; De Man H; Bouche MP; Schueller L; Van Remoortere P; Wigerinck P; Adams E; Hoogmartens J; Van den Mooter G Eur J Pharm Biopharm; 2008 Nov; 70(3):853-60. PubMed ID: 18657611 [TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients. Sánchez-de la Rosa R; Herrera L; Moreno S Clin Ther; 2008 Feb; 30(2):372-81. PubMed ID: 18343275 [TBL] [Abstract][Full Text] [Related]
17. An insight into thermodynamic relationship between polymorphic forms of efavirenz. Chadha R; Arora P; Saini A; Singh Jain D J Pharm Pharm Sci; 2012; 15(2):234-51. PubMed ID: 22579003 [TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of efavirenz vs rilpivirine in HIV patients initiating first-line combination antiretroviral therapy. Bonafede M; Juday T; Lenhart G; Pan K; Hebden T; Correll T J Med Econ; 2013; 16(4):552-9. PubMed ID: 23391157 [TBL] [Abstract][Full Text] [Related]
19. Formulation and development of bicontinuous nanostructured liquid crystalline particles of efavirenz. Avachat AM; Parpani SS Colloids Surf B Biointerfaces; 2015 Feb; 126():87-97. PubMed ID: 25543986 [TBL] [Abstract][Full Text] [Related]
20. A highly concentrated and taste-improved aqueous formulation of efavirenz for a more appropriate pediatric management of the anti-HIV therapy. Chiappetta DA; Hocht C; Sosnik A Curr HIV Res; 2010 Apr; 8(3):223-31. PubMed ID: 20158456 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]